Nobel Prize goes to gene targeting trio

As a child, Mario Capecchi spent four years on the streets in his native Italy, surviving by stealing or begging for food. Today, he's one of three scientists--the other two are Oliver Smithies and Sir Martin Evans--who've won the Nobel prize for medicine, recognition for their collective work on gene targeting, a process that allows researchers to turn genes off and on in mice. Their work involved introducing a genetic alteration in embryonic stem cells which are then injected into a mouse embryo. That development has spurred a huge advance in understanding the role of genes and health--and advanced a myriad number of therapeutic programs.

- see the release from the Nobel Assembly
- read the article from the New York Times

Related Article:
Gene therapy makes a big comeback. Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.